GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » Cash Ratio

CHGCY (Chugai Pharmaceutical Co) Cash Ratio : 2.81 (As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Chugai Pharmaceutical Co's Cash Ratio for the quarter that ended in Jun. 2024 was 2.81.

Chugai Pharmaceutical Co has a Cash Ratio of 2.81. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Chugai Pharmaceutical Co's Cash Ratio or its related term are showing as below:

CHGCY' s Cash Ratio Range Over the Past 10 Years
Min: 1.19   Med: 1.92   Max: 3.2
Current: 2.81

During the past 13 years, Chugai Pharmaceutical Co's highest Cash Ratio was 3.20. The lowest was 1.19. And the median was 1.92.

CHGCY's Cash Ratio is ranked better than
84.92% of 1008 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs CHGCY: 2.81

Chugai Pharmaceutical Co Cash Ratio Historical Data

The historical data trend for Chugai Pharmaceutical Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Cash Ratio Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.86 1.60 1.44 1.19 2.56

Chugai Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.56 3.20 2.81 -

Competitive Comparison of Chugai Pharmaceutical Co's Cash Ratio

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Cash Ratio falls into.



Chugai Pharmaceutical Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Chugai Pharmaceutical Co's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5132.479/2001.764
=2.56

Chugai Pharmaceutical Co's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5166.971/1837.958
=2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (OTCPK:CHGCY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Chugai Pharmaceutical Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.